Hong Sun Joo, Lee Je-Hyeon, Kim Eun Joo, Yang Hea Jung, Park Jae-Seon, Hong Soon-Kwang
Department of Biological Science and Bioinformatics, Myongji University, 116 Myongji-Ro, Cheoin-gu, Yongin, Gyeonggido 17058, Korea.
Dynebio Inc., B-B205 Woolimlions Valley II, 45 Sagimagil-Ro, Jungwon-Gu, Seongnam-Si, Gyeonggi-Do 13209, Korea.
Mar Drugs. 2017 Mar 23;15(4):90. doi: 10.3390/md15040090.
Neoagarooligosaccharides (NAOs), mainly comprising neoagarotetraose and neoagarohexaose, were prepared by hydrolyzing agar with β-agarase DagA from Streptomyces coelicolor, and the anti-obesity and anti-diabetic effects of NAOs on high-fat diet (HFD)-induced obesity in mice were investigated after NAOs-supplementation for 64 days. Compared to the HFD group, the HFD-0.5 group that was fed with HFD + NAOs (0.5%, w/w) showed remarkable reduction of 36% for body weight gain and 37% for food efficiency ratios without abnormal clinical signs. Furthermore, fat accumulation in the liver and development of macrovesicular steatosis induced by HFD in the HFD-0.5 group were recovered nearly to the levels found in the normal diet (ND) group. NAOs intake could also effectively reduce the size (area) of adipocytes and tissue weight gain in the perirenal and epididymal adipose tissues. The increased concentrations of total cholesterol, triglyceride, and free fatty acid in serum of the HFD group were also markedly ameliorated to the levels found in serum of the ND group after NAOs-intake in a dose dependent manner. In addition, insulin resistance and glucose intolerance induced by HFD were distinctly improved, and adiponectin concentration in the blood was notably increased. All these results strongly suggest that intake of NAOs can effectively suppress obesity and obesity-related metabolic syndromes, such as hyperlipidemia, steatosis, insulin resistance, and glucose intolerance, by inducing production of adiponectin in the HFD-induced obese mice.
新琼脂寡糖（NAOs）主要由新琼脂四糖和新琼脂六糖组成，通过用天蓝色链霉菌的β-琼脂酶DagA水解琼脂制备而成。在给小鼠补充NAOs 64天后，研究了其对高脂饮食（HFD）诱导的肥胖的抗肥胖和抗糖尿病作用。与HFD组相比，喂食HFD + NAOs（0.5%，w/w）的HFD-0.5组体重增加显著降低了36%，食物效率比降低了37%，且无异常临床症状。此外，HFD-0.5组肝脏中的脂肪堆积以及HFD诱导的大泡性脂肪变性的发展几乎恢复到正常饮食（ND）组的水平。摄入NAOs还可有效减小肾周和附睾脂肪组织中脂肪细胞的大小（面积）以及组织重量增加。HFD组血清中总胆固醇、甘油三酯和游离脂肪酸浓度的升高在摄入NAOs后也以剂量依赖的方式显著改善至ND组血清中的水平。此外，HFD诱导的胰岛素抵抗和葡萄糖不耐受明显改善，血液中脂联素浓度显著增加。所有这些结果强烈表明，在HFD诱导肥胖的小鼠中，摄入NAOs可通过诱导脂联素的产生有效抑制肥胖以及肥胖相关的代谢综合征，如高脂血症、脂肪变性、胰岛素抵抗和葡萄糖不耐受。
